Estados Unidos · Plataformas y datos · MarketBeat

Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial

Publicado por MarketBeat · Estados Unidos hace 44 min

Braveheart Bio (NASDAQ:BRVE) presented one-year data from a small study of its experimental heart drug BHB-1893 and outlined plans for a fixed-dose trial, as the company advances…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial

También te puede interesar

Franklin (BEN) Q4 2026 Earnings Call Transcript

Gogo reiterates $870M-$895M 2026 revenue guidance while outlining Galileo speeds to over 1 gigabit by 2032

Haiti PM says gang leader Mathias Saintil dead

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

Nasdaq drops into correction territory — here’s what typically happens next

Strawberry Fields (STRW) Q3 2026 Earnings Call Transcript

Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial

Compartir

También te puede interesar

Franklin (BEN) Q4 2026 Earnings Call Transcript

Gogo reiterates $870M-$895M 2026 revenue guidance while outlining Galileo speeds to over 1 gigabit by 2032

Haiti PM says gang leader Mathias Saintil dead

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

Nasdaq drops into correction territory — here’s what typically happens next

Strawberry Fields (STRW) Q3 2026 Earnings Call Transcript